Despite many years of research into the treatment of schizophrenia, it remains a disabling condition afflicting approximately 0.7 to 1.0 percent of, or nearly 2 million, U.S. adults (Keith et al. 1991; Kendler et al. 1996) . Schizophrenia is one of the leading causes of disability, accounting for nearly 5 percent of all disability in established market economies such as the United States (Murray and Lopez 1996) . When viewed at the individual level, data reveal that approximately 50 percent of persons diagnosed with schizophrenia become significantly and permanently disabled (Rupp and Keith 1993) . The onset, with first diagnosis generally occurring in young adulthood, is usually at a time when familial and social investments are at their greatest (Hyman 2000) , and research has supported the view that schizophrenia results in a significant economic burden (Hall et al. 1985; Andrews 1991; Davies and Drummond 1994; Evers and Ament 1995) . U.S. annual health care expenditures are approximately 2.5 times more than prevalence rates of schizophrenia (Rupp and Keith 1993) , and total U.S. health care expenditures for the treatment and care of schizophrenia have been said to be as high as $33 billion per annum (Rice et al. 1991; Miller 1993, 1996) , making it one of the most costly mental illnesses (McGuire 1991; Murray and Lopez 1996) .
In the United States, expenditures are paid for predominantly by government sources, of which Medicaid pays more than Medicare and other government sources (Mark et al. 1996) . Medicaid budgets are hit extremely hard by schizophrenia. For example, in a recent study (Martin and Miller 1998) , we showed the prevalence of schizophrenia in a continuously eligible Medicaid population for the State of Georgia to be 6.02 percent. The direct medical cost to treat these patients from 1991 to 1993 was over $5,300 per recipient per annum. This Medicaid esti-mate was conservative, as it did not include the cost of care provided at State-operated inpatient mental institutions, likely a significant cost driver in this population. The incredible cost of schizophrenia has a tremendous impact on employers, health care payers, Federal and State public budgets, individual patients, and families of afflicted individuals. Furthermore, these costs fall disproportionately on the poorest of our society and the public sector, which must serve them.
Because of the high costs of treatment, society's ability to make informative policy decisions must rely on accurate data regarding the costs and potential effectiveness of different treatments. Unfortunately, a significant difficulty in quantifying schizophrenia-related treatment costs is the lack of complete patient-level data describing the many health inputs for hospital, drug, and specialist utilization. To address this significant limitation, we created a comprehensive patient-level data base containing multiple categories of care. These categories of care included all physician, psychiatric specialist, hospital, community mental health center (CMHC), and State psychiatric institution episodes of care in addition to all prescription drug therapy, ancillary services, and recipient demographic information for a large number (19, 142) of Medicaid-eligible patients with schizophrenia, schizophreniform disorders, or schizoaffective disorders residing in Georgia from 1990 to 1997. This was accomplished by linking the administrative claims for the Georgia Medicaid system (Georgia Department of Medical Assistance [GDMA]) with patientlevel data describing inpatient utilization at all ten Stateoperated psychiatric institutions. The ten State psychiatric institutions are the only major sources of care for persons with schizophrenia that do not routinely bill Medicaid in the State of Georgia (GDMA 1992 (GDMA , 1994 .
The combined Medicaid and State psychiatric institutional data are a comprehensive source for economic studies because the data include nearly all medical contacts for the treatment of schizophrenia, including prescription benefits, and because Medicaid and the State psychiatric institutions are generally first dollar payers (no deductibles). Additionally, our earlier findings of a 6 percent prevalence of schizophrenia in Georgia Medicaid-eligible persons as compared with the population as a whole suggests that a large portion of these persons residing in the State of Georgia are eligible for Medicaid benefits at one time or another.
To achieve the primary objectives of the article, preliminary objectives were to (1) merge the administrative claims from the GDMA with the treatment history file of the Georgia Department of Human Resources (DHR) describing inpatient utilization received at any one of the ten system inpatient institutions by patient identifier, and then (2) determine the precision and concordance of merging two administrative data sets by patient identifier.
Following merging and validation, the primary objectives of this study were (1) to describe the utilization patterns and associated charges for the treatment of schizophrenia (so that the relationship between costs and service is clarified); (2) to describe the temporal pattern of total direct medical costs associated with schizophrenia (so that the relationships between cost drivers are clarified); (3) to determine the total direct medical costs to treat patients suffering from schizophrenia (so that realistic budgets related to such care can be set); and (4) to forecast future schizophrenia medical costs (so that budgetary decisions, which are usually made well in advance of appropriation of dollars, will be sound). All of these objectives are specific to a Medicaid-eligible population.
Methods
Data Sources. This study linked two existing data sources. The first was the claims history of Medicaid-eligible recipients diagnosed with schizophrenia residing in the State of Georgia. The Medicaid claims data provide information on drug, CMHC, physician, psychiatrist, and general community hospital utilization for each patient. Common resources available to these patients were the ten State psychiatric hospitals, which do not routinely bill Medicaid for services rendered for persons 22 to 64 years of age. To capture these psychiatric episodes of care, the treatment history file and the Hospital Medical Information System file of each of the State psychiatric hospitals were linked by patient identifiers to the Georgia Medicaid claims data. These merged data provided what we feel is a substantially complete picture of the majority of medical resources consumed for each Medicaid-eligible patient with schizophrenia.
Medicaid claims data: GDMA. These data consisted of three files: (1) the recipient file, which contained the demographic profile and eligibility history for each Medicaid enrollee; (2) the prescription file, which contained all prescription transactions reimbursed by the GDMA Drug Program; and (3) the medical history file, which contained information for all reimbursed nondrug medical claims for the study period. This data set is housed at the University of Georgia and is updated annually.
A total of 19,142 persons with schizophrenia were identified and retained by searching the GDMA medical history files from 1990 through 1994 for ICD-9-CM designations in the 295 series of either the primary or secondary diagnosis fields. It is important to note that because ICD 295 codes were used, persons with schizophreniform and schizoaffective disorders are included in our sample. These recipients were downloaded and sent to GDMA to match GDMA-generated scrambled base IDs with Social Security numbers. This procedure had been approved pursuant to the delivery of a signed confidentiality waiver from GDMA. Data describing the Medicaid eligibility, medical utilization, and prescription use from January 1, 1990, through December 31, 1997, for recipients successfully merged with the DHR-based treatment history file were output to construct analytic data sets. This study was reviewed and approved by the University of Georgia and the Georgia DHR Institutional Review Boards.
State-based institutional data: DHR. The treatment history file of the State Client Tracking data base was obtained from the DHR Division of Mental Health, Mental Retardation, and Substance Abuse. The treatment history file contained a systemwide record of each visit a patient had at any one of the ten system inpatient institutions. This file described admission and discharge dates; client demographic information; patient identifiers including name, address, Social Security number, and client identification number; and limited diagnostic information. The only patient identifiers from the treatment history file requested for this study were Social Security number and client identification number. This file was initially merged by Social Security number of the Georgia Medicaid file to identify episodes of institution-based inpatient care. Social Security identifiers were deleted once practical.
To verify the merging procedure, dates of birth (DOBs), race, and gender originating from the DHR and GDMA data sets were compared to determine concordance between the files. The concordance percentage for gender was 99.4 percent and for race 98.8 percent. There were discordant DOBs for 12 percent of persons, but only 2.7 percent had discordant DOBs that differed by more than 1 year. Given the high proportion of recipients with concordant DOBs and the relative parity of discordant DOBs (off by less than 1 year), combined with the very high concordance of gender and race, we concluded that the merging procedure by Social Security number was reliable and that the merged patient-level file could be used for further analyses. Because GDMA used demographics such as DOB and sex in determining eligibility, when there were instances of discordant demographic values, the GDMA demographic information was used. If GDMA demographic information was missing or undetermined, the DHR-based demographic values were used to supplement the GDMA-based demographic variables.
The merged data files then were inspected and subjected to logic checks to identify likely coding errors. A total of 134 potential subjects were deleted from the cohort based on inconsistencies found in the data with regard to inpatient utilization that could not be logically reconciled (i.e., admissions over the same dates at two different institutions). No other logical inconsistencies for the data were identified. Participant Pool. Persons meeting the following eligibility criteria were retained in the schizophrenia cohort: (1) were eligible for Medicaid (GDMA) benefits for at least 1 month in 1990 to 1994; (2) had a primary or secondary ICD-9-CM 295 series designation (U.S. Department of Health and Human Services 1989) (n = 19,142 met first two inclusion criteria); (3) were at least 10 years of age at the study start of January 1, 1990 (n reduced by 461); (4) were at least 16 years of age at the time of their first schizophrenia diagnosis (ICD-9 = 295.**; criterion applied only after the analytic files were created; n reduced by 322); (5) had a Social Security number supplied by GDMA (n reduced by 1,953); (6) had unique GDMA, DHR, and Social Security number identifiers after merging source files (n reduced by 45); and (7) met all logic checks to detect coding errors (n reduced by 134). This left a final cohort of 16,227 persons with a diagnosis for schizophrenia, with over 109,000 personyears of observation in the administrative data set. While we cannot assess directly the impact of the above missing data points, there is no reason to believe there is any systematic bias of the relatively small proportion of persons dropped that would influence the representativeness of the remaining cohort.
Estimating Resource Utilization. Proxies for cost were derived from the total amount paid by Medicaid and Medicare for each reimbursed claim. The amount paid by Medicare was pulled directly from the Medicaid claims file. All resource estimates were adjusted to 1995 dollars using the Medical Care Service Consumer Price Indexes (CPI) for all nonprescription services, and products and prescriptions were adjusted using the CPI specific to prescription drugs (HCFA 1998) .
The DHR file data for the 7,935 recipients with one or more DHR inpatient episodes derived from the entire cohort of 16,227 recipients was merged with the FY 1995 Hospital Budget and Utilization Report (Georgia DHR 1995) by facility, location within the facility, and status code. Budget information based on all facility patients was used to calculate estimated per diem cost by dividing the direct patient care costs incurred within a cost center within each facility by the total days of care delivered within the facility-specific cost centers. Added to that estimate of the direct patient care per diem rates were facility-specific overhead rates that were derived from facility-specific overhead expenditures divided by total patient days within each facility. The sum of the center-and facility-specific direct patient care and facility-specific overhead per diem rates was the estimated total per diem rate. To calculate the cost of each admission, the per diem rate was multiplied by length of stay (LOS). To avoid any instances of doublecounting, the following general rule was followed for reporting LOS and dollars spent: when LOS was reported for inpatient days appearing on both source files, they were reported as DHR hospital days but the amount paid for care was reported as a GDMA inpatient expenditure.
Overview of Analysis. The patient-level merged data were aggregated by category of service (COS; inpatient hospital, State psychiatric hospital, outpatient mental health center, other outpatient physician/psychiatry care, and prescription) and are reported as costs per patient per year for each of the 8 years of the study. The number of care provider contacts as well as the costs associated with those contacts is described. Costs were disaggregated by schizophrenia-and nonschizophrenia-related care. Total schizophrenia-related medical costs were determined by summing over all COSs and identifying claims with a primary ICD-9-CM diagnosis of 295.**. Specific cost drivers of schizophrenia-based care were further abstracted, including the array of care given in the State psychiatric hospitals, CMHCs, and prescription drug categories.
To describe the temporal pattern of expenditures, autoregressive integrated moving average (ARIMA) time series models were estimated for the 8 years of total cost data broken into monthly time units of expenditures per eligible patient (per member per month [PMPM] ). Identification of the best fit for the time series models was based upon inspection of the time series, the autocorrelation function (ACF), the inverse autocorrelation function (IACF), and the partial autocorrelation function (PACF) plots to identify whether the series needed to be differenced and to identify any AR or MA processes (McDowall et al. 1980) . The data were differenced to detrend the time series and fit with AR and MA terms based on the ACF, PACF, and IACF plots. When necessary, the models were reestimated based upon the diagnostics of the fitted model. Q statistics were output; in all final models, they were nonsignificant, indicating that the estimated time series models were absent of serial autocorrelation. The ARIMA time series models then were used to forecast expenditures 5 years into the future, or until the end of 2002. This was done for aggregate Medicaid and DHR expenditures and by each COS relevant to schizophrenia.
All data manipulation and analyses were performed on an IBM 9672-R83 mainframe computer using a TSO (Time-Sharing Option) connection and ISPF (Interactive System Productivity Facility) editor to manipulate data and invoke SAS version 6.11.
Results
Demographics of Schizophrenia Cohort. Table 1 describes the demographics of recipients by those with and without a DHR inpatient episode. The majority of persons with schizophrenia retained in this analysis were women, representing just over 60 percent of the cohort. However, 58 percent of men in the cohort experienced an episode in one of the ten DHR-operated facilities, whereas only 43 percent of women had one or more DHR inpatient episodes (x 2 = 310.3; p < 0.001). A majority of those with schizophrenia were black (58%), with whites accounting for 36 percent of those in the cohort. There was no difference in the racial composition between those with and without a DHR episode (x 2 = 0.644; p -0.422). Very few persons of those with race identified were of a race other than black or white (< 1 %). The average age of the entire cohort was 40 years at the beginning of the study period. The average age of those experiencing a DHR inpatient episode was 36 years, compared with 43 years for those without a DHR experience (f = 36.4; p < 0.001). The age of the respondents clustered around the third and fourth decades of life, with a majority of persons between the ages of 20 and 39 years in the cohort. Fewer than 7 percent of persons were less than 20 years, and fewer than 12 percent were 60 years or older. Persons aged 10 to 15 years (age on January 1, 1990) were the least likely to have a schizophrenia diagnosis and made up only 1.9 percent of the total cohort.
Over 51 percent of the cohort was continuously eligible for Medicaid benefits from January 1990 through December 31, 1997. Approximately 46 percent of those with a DHR inpatient episode had continuous eligibility with GDMA throughout the study period. The average length of eligibility was 81 months (standard deviation [SD] 22.2) for the entire cohort, 79.8 months (SD 22.3) for those with at least one DHR inpatient episode, and 82.1 (SD 21.9) for those without a DHR inpatient episode (r = 6.54; p< 0.001).
Resource Utilization. From January 1990 to December 1997, there were 4.8 million claims paid by Medicaid, over 300,000 inpatient hospital days, and over 2.4 million days of nursing home/long-term care paid by Medicaid for the cohort of 16,227 persons suffering from schizophrenia. From January 1990 to August 1996, there were an additional 31,571 admissions to DHR facilities, corresponding to over 975,000 days of care not reimbursed by Medicaid. DHR data were not available after August 1996, and thus DHR data are understated for the entire time frame (through September 1997). The exact amount understated is unknown, but if we compare the months available for the data in which there were 93 months for Medicaid data and 80 months for DHR data, the DHR expenditures would be underestimated by about 14 percent relative to Medicaid expenditures. This may be a high estimate because DHR expenditures were decreasing prior to the time when data became unavailable.
Total Medicaid, Medicare, and nonreimbursed DHR institutional expenditures totaled in excess of $1.04 billion from January 1990 to December 1997 expressed in 1995 constant dollars, equivalent to $9,950 per member per year (PMPY). Medicaid, Medicare, and nonreimbursed DHR expenditures over the same period in 1995 constant dollars were $720 million (or $6,564 PMPY), $67 million (or $612 PMPY), and $258 million (or $2,355 PMPY), respectively. In unadjusted dollars, Medicaid paid $660 million (or $6,026 PMPY) and Medicare paid $63 million (or $575 PMPY) to care for the cohort of 16,227 recipients. It should be noted that the estimates for nonreimbursed DHR institutional care are understated relative to Medicaid expenditures because data were not available after August 1996.
The cost estimates for DHR and Medicaid expenditures disaggregated into COSs are shown in figure 1 for 1990 to 1997. DHR institutional care dominated the cost of care, while care delivered at CMHCs, private longterm care facilities (private LTCs), and inpatient hospitals composed a significant portion of the cost, with expenditures for each in excess of $100 million over the study period.
In relative terms, over 30 percent of costs for these patients' care went to DHR inpatient care in 1990, compared with 26.7 percent in 1995 (figure 2). Making up for this decrease in the proportion of care delivered at DHR sites is an increase in costs for prescription drugs between 1990 and 1995, where the percentage of costs allocated to prescription drugs went from 5.7 percent of total expenditures to 10.5 percent. Also increasing were private LTC expenditures, which rose from 12.9 percent to 15.6 percent of the total. CMHC expenditures remained stable at 19 percent over the 1990 to 1995 period. Noteworthy was a relative decrease in inpatient hospital expenditures paid by Medicaid. Table 2 describes costs by category, select years of service (1990, 1995) , and the total time period in amounts adjusted to 1995 constant dollars. Table 3 shows costs broken down by schizophrenia-related (first diagnosis code = 295) and nonschizophrenia-related Medicaid and Medicare claims, adjusted to 1995 constant dollars. This does not reflect the substantial impact of State hospitalization costs described later. More than one-third of total costs (38.6%) appeared to be going to care specific to schizophrenia, although this was a conservative estimate, as many providers are not required to use ICD-9-CM codes (e.g., transportation) and, consequently, some care is not tallied as schizophrenia care even though it may be directly related. It is important to note that, in our population, virtually no schizophrenia-related costs were attributed to Medicare. Furthermore, ICD-9-CM codes typically are not paired to prescription claims. To present prescription costs for schizophrenia-versus nonschizophrenia-related claims, we followed the same rationale used in an earlier publication (Martin et al. 2001 ) on prescription medication costs in this cohort. Prescription claims were divided into psychotropic (schizophreniarelated category) and nonpsychotropic (nonschizophreniarelated category) medications.
A total of 868,922 days of inpatient utilization occurred in the ten DHR facilities from 1990 to 1995 at a cost of more than $229 million (table 4) . From 1990 to 1995, DHR inpatient costs decreased from a total expenditure of approximately $41 million in 1990 to approximately $26 million in 1995. As can be seen in the table, patient numbers per year stayed relatively constant while dollar amount per patient spent and LOS declined. A breakdown of DHR facility costs (table 5) indicates that a majority of the care in DHR facilities was for adult mental health, which accounted for approximately 83 percent of all hospital days and approximately 83 percent of costs. Forensic inpatient services (mental health-related incarceration) and extended care accounted for 4 percent and 10 percent of the total costs, with all remaining categories of mental health care accounting for approximately 4 percent of the total hospital days and costs.
Expenditure Forecasts. Many recipients were not continuously eligible for Medicaid benefits during the study, and the temporal patterns of costs were affected by this eligibility variation. To gain a sense of the temporal pattern of total costs and cost by major category, the average recipient cost PMPM was calculated by dividing the monthly cost by the number of persons eligible that month, repeated for each month of the study. Because Medicaid data were available for 8 years, 96 monthly time periods were possible. Because data for 1997 were not completely adjudicated, all Medicaid data for the last 3 months of 1997 were discarded for these monthly analyses, for a total of 93 time points from January 1990 to September 1997. These PMPM expenditures then were used and fit with ARIMA models, and ARIMA coefficients were used to forecast expenditures through 2002.
Because theoretically anybody living in the State of Georgia is eligible to be admitted into one of the ten State DHR facilities, PMPM expenditures for DHR utilization and costs were calculated two ways. The first method divided the monthly DHR inpatient episodes by 16,227 (number of persons in cohort). This method, however, may be biased because persons dying or leaving the State or moving to the State in the middle of the study time period should not be counted in the denomi- nator for those months because they do not reside in the State. Because neither censuslike data nor death certificate data were available to link with these files, a conservative alternative method was used to calculate PMPM DHR expenditures in which only costs for persons that were continuously eligible for Medicaid benefits from 1990 through 1995 were tallied in each month and subsequently divided by the total number of recipients that were continuously eligible (approximately 50% of cohort). The logic for analyzing only those that were continuously eligible is that Medicaid eligibility is a very good indicator that a person is still alive and is living within the State.
Results of the PMPM time series forecasts for aggregate Medicaid and Medicare, prescription, DHR expenditures for all subjects, and DHR expenditures for continuously eligible subjects, in 1995 constant dollars, are found in figures 3 to 6.
While the temporal pattern of nominal costs is increasing, total Medicaid and Medicare expenditures in 1995 constant dollars were unchanging at approximately $700 PMPM (figure 3). In contrast, prescription expenditures increased dramatically, from around $50 PMPM in 1990 to $100 PMPM in 1997 (figure 4). These expenditures were projected to increase to more than $150 PMPM by 2002. The temporal pattern of DHR expenditures varied depending on whether the entire cohort was used (figure 5) or the continuously eligible cohort was used (figure 6) but generally indicated a decrease in expenditures. The PMPM expenditures were somewhat lower for persons continuously eligible for Medicaid than for the total cohort. Note.-CMHC = community mental health center; LTC = long-term care facility. 1 Expressed in thousands of dollars.
Discussion
Our comprehensive data indicate that the State resources being allocated and used to treat persons with schizophrenia are enormous. Costs totaled more than $1 billion over an 8-year period when expressed in 1995 constant dollars. Most of these costs were paid by Medicaid, at approximately $700 PMPM (with some additional costs accounted for by Medicare). This is in comparison to the additional costs of approximately $200 PMPM paid by DHR.
As an individual COS, DHR institutional care dominated the cost of care. However, in proportion to other costs, DHR expenditures appeared to have decreased significantly over time and appear likely to continue to decrease. These findings do not seem to be specific to only changes in State allocations, as the Medicaid-paid inpatient expenditures mirrored the DHR decrease as well. 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Note.-PMPM = per member per month. Note.-DHR = Georgia Department of Human Resources; LOS = length of stay. 1 Mental health service for a patient over 18 years of age whose expected LOS is more than a year.
2 Service for a patient who has an emotional or mental disorder and who has a physical or medical problem that requires significant medical and nursing skills available on a 24-hour basis for therapeutic and/or rehabilitation interventions. 3 Not otherwise categorized.
Partially offsetting the decrease in inpatient expenditures is the very substantial increase in prescription drug costs between 1990 and 1995. These costs rose from 5.7 percent to 10.5 percent of expenditures. This increase in expenditures likely reflects the rapid adoption of atypical neuroleptic medications (e.g., clozapine, risperidone, olanzapine), which are expensive. In some support of this idea is a study of the longitudinal drug costs from this same cohort (Martin et al. 2001) , in which we presented preliminary evidence for increased expenditures related to these newer medications. Pharmacoeconomic modeling studies have indicated that prescribing higher-acquisitioncost atypicals is cost-neutral or cost-saving where the higher drug costs are offset by reductions in care in inpatient settings (Revicki 1999) . Although in this study we did not intend to determine whether atypicals are costneutral or cost-saving, the time series evidence supports the notion that over an entire system of care, as more atypicals are used, drug costs increase and inpatient costs decrease such that the inflation-adjusted trends in the system costs remain relatively constant. Naturally, because of the retrospective panel design of this study, a causal relationship cannot be established between the use of atypicals and total system costs. Another finding from our analysis that bears discussion is the finding of relatively stable cost changes in the area of CMHCs. Our data suggest that real costs of CMHC services in the State of Georgia have changed very little.
Finally, the PMPM expenditures were somewhat lower for persons continuously eligible for Medicaid than for the total cohort. This finding suggests that persons who are eligible for Medicaid benefits are less likely to utilize the DHR facilities. Why this is so remains unclear but may suggest that Medicaid benefits and, perhaps, access to medications or alternative hospital settings may be a substitute for State-based institutional care. Because Medicaid benefits are not affected directly by admission to a DHR facility in Georgia, this relationship between continuous Medicaid eligibility and fewer DHR admissions is unlikely a result of Medicaid eligibility criteria. If these explanations are shown to be accurate, particularly medication access, they could have significant policy implications regarding Medicaid eligibility criteria.
Given the recent treatment recommendations as outlined initially in the Schizophrenia Patient Outcomes Research Team results (Lehman et al. 1998a ) and more recently in the Expert Consensus Panels for Schizophrenia Guidelines (McEvoy et al. 1999) , our findings of significant resource utilization changes over time warrant continued examination. Recommendations have suggested the need for neuroleptic medication as a first line therapy followed by selected outpatient services from multiple service delivery systems and multiple intervention strategies. Service delivery systems recommended include assertive community treatment, psychosocial rehabilitation, vocational rehabilitation, and case management. Intervention strategies include patient and family education, medication and symptom monitoring, and cognitive and social skills training. A qualitative look at our findings suggests that specific to funding, particularly CMHC funding, resource outlays do not reflect those recommendations.
The devastating social and economic burden of schizophrenia is elucidated in a number of ways from our data and exemplifies schizophrenia's negative impact. The finding that greater than half of the cohort was continuously eligible for Medicaid for the entire 8 years of the study reflects the chronicity of the disorder, even with current therapies. The high number of individuals having at least one episode necessitating admission to a DHR hospital, the largest cost driver, exemplifies the severity and functional impact of the disorder. Finally, the relatively high proportion (more than one-third) of health costs directly related to the schizophrenia diagnosis points to schizophrenia's pervasive negative effect on the individual's overall health and well-being.
Several noteworthy limitations of the study should be acknowledged. First, the time series forecasts are based on only the trends observed in prior periods and do not account for future changes in policy or technology. For example, it is possible that, with the advent of newer medications or the availability of generic versions, pharmacy costs could change, leveling off or even decreasing. Also, the costs used in this analysis came from two sources, Medicaid claims data and the DHR treatment history file. Because Medicare data were not available, the Medicare paid amounts, when reported, were determined from the Medicaid claims records for dually eligible persons and were not verified with matched Medicare claims. Because DHR costs were arrived at using institution-and wardspecific average per diem rates calculated from an annual budget report, variability in actual costs for DHR inpatient utilization could not be determined, and average per diem rates may not reflect actual resource use, particularly for very short and very long stays.
Current recommendations as to the treatment of persons with schizophrenia point to an increase in pharmacological intervention using prescription medications of higher direct cost, integrated with aggressive community support and assistance. Cost trends as suggested by our data do seem to show an increase in reliance on medication treatment, and probably the newer neuroleptic medications. However, costs for other services have either remained stable (e.g., CMHC expenditures) or decreased (e.g., inpatient expenditures). If prescription costs continue to rise as predicted, either Medicaid expenditures will have to rise overall or these secondary service expenditures will need to be reduced.
